SG11201805888SA - Cyclic dinucleotides for treating conditions associated with sting activity such as cancer - Google Patents
Cyclic dinucleotides for treating conditions associated with sting activity such as cancerInfo
- Publication number
- SG11201805888SA SG11201805888SA SG11201805888SA SG11201805888SA SG11201805888SA SG 11201805888S A SG11201805888S A SG 11201805888SA SG 11201805888S A SG11201805888S A SG 11201805888SA SG 11201805888S A SG11201805888S A SG 11201805888SA SG 11201805888S A SG11201805888S A SG 11201805888SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cancer
- pct
- sting
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277273P | 2016-01-11 | 2016-01-11 | |
| US201662436759P | 2016-12-20 | 2016-12-20 | |
| PCT/US2017/013066 WO2017123669A1 (en) | 2016-01-11 | 2017-01-11 | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805888SA true SG11201805888SA (en) | 2018-08-30 |
Family
ID=58010371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805888SA SG11201805888SA (en) | 2016-01-11 | 2017-01-11 | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10604542B2 (enExample) |
| EP (1) | EP3402801B1 (enExample) |
| JP (1) | JP6867395B2 (enExample) |
| KR (2) | KR102789862B1 (enExample) |
| CN (1) | CN109451740B (enExample) |
| AU (1) | AU2017207757B2 (enExample) |
| BR (1) | BR112018013808A2 (enExample) |
| CA (1) | CA3011528A1 (enExample) |
| CL (1) | CL2018001870A1 (enExample) |
| CO (1) | CO2018008196A2 (enExample) |
| DK (1) | DK3402801T3 (enExample) |
| EA (1) | EA036421B1 (enExample) |
| ES (1) | ES3046957T3 (enExample) |
| FI (1) | FI3402801T3 (enExample) |
| HR (1) | HRP20251050T1 (enExample) |
| IL (1) | IL260427B (enExample) |
| LT (1) | LT3402801T (enExample) |
| MX (1) | MX2018008266A (enExample) |
| MY (1) | MY194058A (enExample) |
| PE (1) | PE20181330A1 (enExample) |
| PL (1) | PL3402801T3 (enExample) |
| PT (1) | PT3402801T (enExample) |
| RS (1) | RS67188B1 (enExample) |
| SG (1) | SG11201805888SA (enExample) |
| SI (1) | SI3402801T1 (enExample) |
| SM (1) | SMT202500412T1 (enExample) |
| WO (1) | WO2017123669A1 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3746B1 (ar) | 2015-03-10 | 2021-01-31 | Aduro Biotech Inc | تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون" |
| CA2995365C (en) | 2015-08-13 | 2021-10-12 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| CN109451740B (zh) * | 2016-01-11 | 2022-09-02 | 先天肿瘤免疫公司 | 用于治疗与sting活性相关的病症诸如癌症的环状二核苷酸 |
| MX390014B (es) | 2016-03-18 | 2025-03-20 | Immune Sensor Llc | Compuestos de dinucleótidos cíclicos y métodos de uso. |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| TWI689514B (zh) | 2016-07-06 | 2020-04-01 | 美商史貝羅威生物科學有限公司 | 化合物、組合物及用於治療疾病之方法 |
| BR112019004042A2 (pt) | 2016-08-30 | 2019-05-28 | Dana-Farber Cancer Institute, Inc. | composições de liberação de fármaco e usos das mesmas |
| CR20190168A (es) | 2016-10-04 | 2019-05-17 | Merck Sharp & Dohme | Compuestos de benzo[b]tiofeno como agonistas de sting |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
| SG11201908813QA (en) | 2017-04-13 | 2019-10-30 | Aduro Biotech Holdings Europe B V | Anti-sirp alpha antibodies |
| WO2018208667A1 (en) | 2017-05-12 | 2018-11-15 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| US11259980B2 (en) | 2017-07-31 | 2022-03-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Soft inflatable exosuit for knee rehabilitation |
| MA49772A (fr) | 2017-08-04 | 2021-04-21 | Merck Sharp & Dohme | Agonistes benzo[b]thiophène de sting pour le traitement du cancer |
| WO2019027857A1 (en) | 2017-08-04 | 2019-02-07 | Merck Sharp & Dohme Corp. | COMBINATIONS OF PD-1 ANTAGONISTS AND STING BENZO [B] THIOPHENIC AGONISTS FOR THE TREATMENT OF CANCER |
| CA3073919A1 (en) | 2017-08-30 | 2019-03-07 | Beijing Xuanyi Pharmasciences Co., Ltd. | Cyclic di-nucleotides as stimulator of interferon genes modulators |
| EP3675859A4 (en) | 2017-08-31 | 2021-06-30 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISEASE |
| JP7316263B2 (ja) * | 2017-08-31 | 2023-07-27 | ブリストル－マイヤーズ スクイブ カンパニー | 抗癌剤としての環状ジヌクレオチド |
| WO2019051488A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
| WO2019051489A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
| CN111465610A (zh) | 2017-09-14 | 2020-07-28 | 詹森生物制药有限公司 | 经修饰核苷亚磷酰胺 |
| EP3694867B1 (en) * | 2017-10-10 | 2025-12-24 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| WO2019092660A1 (en) | 2017-11-10 | 2019-05-16 | Takeda Pharmaceutical Company Limited | Sting modulator compounds, and methods of making and using |
| EP3728282B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
| WO2019125974A1 (en) | 2017-12-20 | 2019-06-27 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| EP3505527A1 (en) * | 2017-12-29 | 2019-07-03 | Invivogen | Cyclic dinucleotides for cytokine induction |
| US10519187B2 (en) * | 2018-02-13 | 2019-12-31 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| WO2019173587A1 (en) * | 2018-03-08 | 2019-09-12 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| US20210015915A1 (en) | 2018-03-23 | 2021-01-21 | Takeda Pharmaceutical Company Limited | Sting modulator compounds with sulfamate linkages, and methods of making and using |
| US11702430B2 (en) | 2018-04-03 | 2023-07-18 | Merck Sharp & Dohme Llc | Aza-benzothiophene compounds as STING agonists |
| CN111971277B (zh) | 2018-04-03 | 2023-06-06 | 默沙东有限责任公司 | 作为sting激动剂的苯并噻吩及相关化合物 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| WO2019227007A1 (en) | 2018-05-25 | 2019-11-28 | Incyte Corporation | Tricyclic heterocyclic compounds as sting activators |
| WO2020014127A1 (en) | 2018-07-10 | 2020-01-16 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| TW202030199A (zh) * | 2018-07-17 | 2020-08-16 | 美商健生生物科技公司 | 作為ｓｔｉｎｇ促效劑之環狀二核苷酸 |
| US10875872B2 (en) | 2018-07-31 | 2020-12-29 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| US11008344B2 (en) | 2018-07-31 | 2021-05-18 | Incyte Corporation | Tricyclic heteroaryl compounds as STING activators |
| MX2020013322A (es) | 2018-08-16 | 2021-02-22 | Eisai R&D Man Co Ltd | Sales de compuestos y cristales de los mismos. |
| MX2021002107A (es) | 2018-09-06 | 2021-04-28 | Daiichi Sankyo Co Ltd | Derivado de dinucleotido ciclico novedoso y conjugado de anticuerpo-farmaco del mismo. |
| SG11202101980VA (en) | 2018-09-12 | 2021-03-30 | Silverback Therapeutics Inc | Methods and composition for the treatment of disease with immune stimulatory conjugates |
| KR102755652B1 (ko) | 2018-09-21 | 2025-01-21 | 상하이 드 노보 파마테크 컴퍼니 리미티드 | 고리형 디뉴클레오티드 유사체, 이의 약학 조성물 및 용도 |
| WO2020092127A1 (en) | 2018-10-29 | 2020-05-07 | Venenum Biodesign, LLC | Novel sting agonists |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| WO2020089815A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Antibody conjugates comprising sting agonist |
| US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
| MX2021006498A (es) * | 2018-12-04 | 2021-07-06 | Bristol Myers Squibb Co | Proceso para la preparacion de un dinucleotido ciclico. |
| US12129267B2 (en) | 2019-01-07 | 2024-10-29 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| EP3921323A1 (en) | 2019-02-05 | 2021-12-15 | Bristol-Myers Squibb Company | Synthesis of 1,2,5-tri-0-benz0yl-3-dibenzylamin0-3-de0xyrib0se as intermediate for producing 3'-amino-3'-deoxyadenosine and 3'-amino-3'-deoxyguanosine and the protected derivatives thereof |
| CA3139809A1 (en) | 2019-05-10 | 2020-11-19 | Takeda Pharmaceutical Company Limited | Antibody drug conjugates |
| CN114340680A (zh) | 2019-07-05 | 2022-04-12 | 坦博公司 | 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途 |
| US12435104B2 (en) * | 2019-07-25 | 2025-10-07 | Beigene, Ltd. | Cyclic dinucleotides as sting agonists |
| WO2021067644A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| CA3165956A1 (en) | 2019-12-26 | 2021-07-01 | National University Corporation Tokai National Higher Education And Research System | Polynucleotide and pharmaceutical composition |
| WO2021168274A1 (en) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| AU2021230226B2 (en) | 2020-03-06 | 2025-06-26 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate including novel cyclic dinucleotide derivative |
| WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
| EP4138852A4 (en) * | 2020-04-21 | 2024-05-15 | Duke University | COMPOSITIONS AND METHODS FOR TREATING PAIN |
| AU2021270347A1 (en) | 2020-05-11 | 2022-12-15 | Erytech Pharma | Red cell extracellular vesicles (RCEVs) containing cargoes and methods of use and production thereof |
| IL299508A (en) | 2020-07-01 | 2023-02-01 | Ars Pharmaceuticals Inc | Anti-asgr1 antibody conjugates and uses thereof |
| EP4192506A1 (en) | 2020-08-07 | 2023-06-14 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| JPWO2022050300A1 (enExample) | 2020-09-02 | 2022-03-10 | ||
| AU2021359844A1 (en) * | 2020-10-15 | 2023-05-04 | The Regents Of The University Of Michigan | Crystalline polymorphic forms of sting agonists associated with metal ions capable of modulating an immune response |
| KR102466750B1 (ko) * | 2020-10-23 | 2022-11-15 | 아주대학교산학협력단 | 인돌리진 유도체를 유효성분으로 포함하는 인터페론 유전자 자극제 조성물 |
| KR20230141754A (ko) | 2020-10-30 | 2023-10-10 | 아박타 라이프 사이언시스 리미티드 | Fap-활성화 혈청 반감기 연장된 치료 접합체 |
| JP7397996B2 (ja) | 2020-11-09 | 2023-12-13 | 武田薬品工業株式会社 | 抗体薬物コンジュゲート |
| AU2022302611A1 (en) | 2021-06-30 | 2024-02-15 | Kyowa Kirin Co., Ltd. | Polynucleotide and medicinal composition |
| JPWO2023167238A1 (enExample) | 2022-03-02 | 2023-09-07 | ||
| AU2023336004A1 (en) | 2022-08-29 | 2025-03-06 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate including mutant fc region |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| AU2003244088A1 (en) | 2002-06-20 | 2004-01-06 | Nippon Suisan Kaisha, Ltd. | Produrg, medicinal utilization thereof and process for producing the same |
| EP1740192B1 (en) * | 2004-03-15 | 2012-06-13 | David K. R. Karaolis | Cyclic dinucleotide for stimulating the immune of inflammatory response |
| KR102702287B1 (ko) * | 2012-05-15 | 2024-09-04 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법 |
| WO2013185052A1 (en) | 2012-06-08 | 2013-12-12 | Aduro Biotech | Compostions and methods for cancer immunotherapy |
| BR112015013440B1 (pt) | 2012-12-13 | 2020-12-08 | Aduro Biotech, Inc | composições compreendendo dinucleotídeos de purina cíclicos com estereoquímicas |
| CA2908154C (en) * | 2013-04-29 | 2023-11-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| SI2996473T1 (sl) | 2013-05-18 | 2019-12-31 | Aduro Biotech, Inc. | Sestavki in postopki za aktiviranje signaliziranja, odvisnega od "stimulator interferonskih genov" |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| AU2014340269B2 (en) | 2013-10-21 | 2018-06-21 | Drexel University | Use of STING agonists to treat chronic hepatitis B virus infection |
| WO2015077354A1 (en) | 2013-11-19 | 2015-05-28 | The University Of Chicago | Use of sting agonist as cancer treatment |
| US20150144176A1 (en) | 2013-11-22 | 2015-05-28 | Massachusetts Institute Of Technology | Photovoltaic power balancing and differential power processing |
| US9315523B2 (en) | 2013-12-06 | 2016-04-19 | Rutgers, The State University Of New Jersey | Cyclic dinucleosides |
| ES2692226T3 (es) | 2014-06-04 | 2018-11-30 | Glaxosmithkline Intellectual Property Development Limited | Dinucleótidos cíclicos como moduladores de STING |
| US10011630B2 (en) | 2014-12-16 | 2018-07-03 | Invivogen | Cyclic dinucleotides for cytokine induction |
| US20170340658A1 (en) | 2014-12-16 | 2017-11-30 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| JO3746B1 (ar) | 2015-03-10 | 2021-01-31 | Aduro Biotech Inc | تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون" |
| CA2995365C (en) | 2015-08-13 | 2021-10-12 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| CR20180286A (es) | 2015-12-03 | 2018-07-16 | Glaxosmithkline Ip Dev Ltd | Dinucleotidos de purina cíclicos como moduladores de sting |
| CN109451740B (zh) * | 2016-01-11 | 2022-09-02 | 先天肿瘤免疫公司 | 用于治疗与sting活性相关的病症诸如癌症的环状二核苷酸 |
| MX390014B (es) | 2016-03-18 | 2025-03-20 | Immune Sensor Llc | Compuestos de dinucleótidos cíclicos y métodos de uso. |
-
2017
- 2017-01-11 CN CN201780015198.2A patent/CN109451740B/zh active Active
- 2017-01-11 AU AU2017207757A patent/AU2017207757B2/en active Active
- 2017-01-11 KR KR1020187022863A patent/KR102789862B1/ko active Active
- 2017-01-11 FI FIEP17704338.7T patent/FI3402801T3/fi active
- 2017-01-11 PL PL17704338.7T patent/PL3402801T3/pl unknown
- 2017-01-11 US US15/748,685 patent/US10604542B2/en active Active
- 2017-01-11 RS RS20250892A patent/RS67188B1/sr unknown
- 2017-01-11 EP EP17704338.7A patent/EP3402801B1/en active Active
- 2017-01-11 MX MX2018008266A patent/MX2018008266A/es unknown
- 2017-01-11 BR BR112018013808-8A patent/BR112018013808A2/pt active Search and Examination
- 2017-01-11 KR KR1020257010190A patent/KR20250049441A/ko active Pending
- 2017-01-11 DK DK17704338.7T patent/DK3402801T3/da active
- 2017-01-11 CA CA3011528A patent/CA3011528A1/en active Pending
- 2017-01-11 PT PT177043387T patent/PT3402801T/pt unknown
- 2017-01-11 EA EA201891565A patent/EA036421B1/ru not_active IP Right Cessation
- 2017-01-11 MY MYPI2018702369A patent/MY194058A/en unknown
- 2017-01-11 JP JP2018536116A patent/JP6867395B2/ja active Active
- 2017-01-11 SM SM20250412T patent/SMT202500412T1/it unknown
- 2017-01-11 LT LTEPPCT/US2017/013066T patent/LT3402801T/lt unknown
- 2017-01-11 ES ES17704338T patent/ES3046957T3/es active Active
- 2017-01-11 SG SG11201805888SA patent/SG11201805888SA/en unknown
- 2017-01-11 PE PE2018001267A patent/PE20181330A1/es unknown
- 2017-01-11 HR HRP20251050TT patent/HRP20251050T1/hr unknown
- 2017-01-11 SI SI201731621T patent/SI3402801T1/sl unknown
- 2017-01-11 WO PCT/US2017/013066 patent/WO2017123669A1/en not_active Ceased
-
2018
- 2018-07-04 IL IL260427A patent/IL260427B/en active IP Right Grant
- 2018-07-10 CL CL2018001870A patent/CL2018001870A1/es unknown
- 2018-08-02 CO CONC2018/0008196A patent/CO2018008196A2/es unknown
-
2020
- 2020-01-31 US US16/778,281 patent/US10961270B2/en active Active
-
2021
- 2021-01-28 US US17/160,578 patent/US11505571B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805888SA (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
| SG11201804787UA (en) | Human immunodeficiency virus neutralizing antibodies | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201810801QA (en) | Brain delivery protein | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201900132QA (en) | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy | |
| SG11201809594WA (en) | Nicotine particles and compositions | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201805001UA (en) | Method of treating influenza a |